Core Viewpoint - Changyang Technology announced the election of Mr. Chen Zhe as the employee representative director of the fourth board of directors during the employee representative meeting held on November 13, 2025 [1] Group 1 - The employee representative meeting was convened on November 13, 2025 [1] - The agenda included the proposal for the election of the fourth board of directors' employee representative director [1] - The proposal to elect Mr. Chen Zhe was approved by the meeting [1]

证券代码：688299 证券简称：长阳科技 公告编号：2025-053 宁波长阳科技股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 （一） 股东大会召开的时间：2025 年 11 月 13 日 （二） 股东大会召开的地点：宁波市江北区庆丰路 999 号公司一楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 141 | | --- | --- | | 普通股股东人数 | 141 | | 2、出席会议的股东所持有的表决权数量 | 56,621,999 | | 普通股股东所持有表决权数量 | 56,621,999 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 20.0580 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 20.0580 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提 ...

国浩律师（上海）事务所 法律意见书 中国 上海 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼，200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China, 200085 电话/TEL: (8621) 5234-1668 传真/FAX: (8621) 5234-1670 关于宁波长阳科技股份有限公司 2025年第四次临时股东大会的法律意见书 致：宁波长阳科技股份有限公司 国浩律师（上海）事务所（以下简称"本所"）接受宁波长阳科技股份有限公 司（以下简称"公司"）委托，指派本所律师出席公司 2025 年第四次临时股东大 会（以下简称"本次股东大会"）。本所律师根据《中华人民共和国证券法》（以 下简称"《证券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规、部门规 章和规舃性文件以及《宁波长阳科技股份有限公司章程》（以下简称"《公司章 程》"）的规定，就公司本次股东大会的召集与召开程序、出席会议人员资格、 召集人 ...

关于选举第四届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 宁波长阳科技股份有限公司（以下简称"公司"）于 2025 年 11 月 13 日召 开 2025 年第四次临时股东大会审议通过《关于取消监事会、增加董事会人数并 修订<公司章程>的议案》，根据修订后的《公司章程》，公司董事会由 8 名董事组 成，其中独立董事 3 名、职工代表董事 1 名。董事会中的职工代表董事由公司职 工代表大会选举产生。 证券代码：688299 证券简称：长阳科技 公告编号：2025-052 宁波长阳科技股份有限公司 公司于 2025 年 11 月 13 日召开了职工代表大会，会议审议通过《关于选举 第四届董事会职工代表董事的议案》，同意选举陈哲先生（简历详见附件）为公 司第四届董事会职工代表董事。本次职工代表大会选举产生的职工代表董事，将 与公司其他 7 名董事共同组成公司第四届董事会，任期自本次职工代表大会审议 通过之日起至第四届董事会任期届满之日止。 上述职工代表董事符合《公司法》等法律法规和《公司章程》规定的 ...

Core Viewpoint - Changyang Technology's optical reflective film product ranks first globally in terms of shipment area, and the company has recently been re-certified as a national "Manufacturing Single Champion Enterprise" by the Ministry of Industry and Information Technology [1] Group 1 - The company's reflective film product has achieved the highest shipment area globally [1] - In 2018, the company's reflective film product was awarded the "Single Champion Product" honor by the Ministry of Industry and Information Technology [1] - The recent certification as a national-level "Manufacturing Single Champion Product" has a validity period of three years [1]

Core Insights - The POE film concept has seen a rise of 1.76%, ranking 6th among concept sectors, with 22 stocks increasing in value, including notable gainers such as Tuori New Energy and *ST Green Health, which hit the daily limit, and others like Fulei Ant and Fengguang Co., which rose by 6.99%, 5.05%, and 4.04% respectively [1][2] Market Performance - The top-performing concept sectors today include Cultivated Diamonds with a rise of 6.08%, Perovskite Batteries at 2.98%, and Dairy Industry at 2.37%, while sectors like Chinese AI 50 and Internet Insurance saw declines of -1.76% and -1.43% respectively [2] - The POE film concept attracted a net inflow of 0.84 billion yuan from major funds, with 11 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow. The leading stock in net inflow was Baofeng Energy, with 1.19 billion yuan, followed by Tuori New Energy and Wanhua Chemical with 1.08 billion yuan and 344.73 million yuan respectively [2][3] Fund Flow Analysis - The stocks with the highest net inflow ratios include Tuori New Energy at 50.39%, *ST Green Health at 48.08%, and Dingjide at 12.66% [3] - The detailed fund flow for the POE film concept shows Baofeng Energy with a 2.01% increase and a net inflow of 118.52 million yuan, while Tuori New Energy had a significant increase of 10.13% with a net inflow of 108.44 million yuan [3][4]

Core Insights - The approval of PD-1 inhibitors Keytruda and Opdivo a decade ago has significantly transformed cancer treatment, particularly in lung cancer, melanoma, and lymphoma, marking the beginning of the immunotherapy era [1] - As key patents near expiration and biosimilars enter the market, the market share of leading products is under pressure, with Merck's Keytruda sales growth slowing to 8% and BMS's Opdivo experiencing a 1% decline [1] - The oncology market is evolving into a "2.0 era," with companies like Merck and BMS focusing on combination therapies involving PD-1 and ADCs to maintain competitive advantages [1][2] Industry Overview - The global oncology drug market is projected to grow from $168 billion in 2020 to $247 billion by 2024, with a compound annual growth rate (CAGR) of 10.2%, while the ADC market is expected to exceed $35 billion with a CAGR of 41.7% [1] - The shift in market dynamics indicates a move towards a multi-target competition era, emphasizing ADCs and combination therapies [1] Company Strategies - Merck is actively building a "PD-1+ADC" treatment matrix through acquisitions and partnerships, aiming to extend the lifecycle of Keytruda [2] - Recent FDA approvals for combination therapies, such as Keytruda with Padcev for bladder cancer, highlight the potential for these combinations to change clinical practices [3] - BMS has also expanded its combination therapies, with its dual immunotherapy for liver cancer becoming the first approved in China [3] Domestic Innovations - Chinese biotech companies are rapidly advancing in the "PD-1+ADC" space, with companies like Junshi Biosciences reporting promising clinical data for their PD-L1 ADC, HLX43, in non-small cell lung cancer [4] - The industry is moving towards "dual antibodies/multi-antibodies + ADC" strategies, with companies like Rongchang Bio and Pfizer exploring innovative combinations [5] Future Directions - The next generation of IO and ADC therapies is expected to become a focal point for multinational corporations in the oncology sector, with a strong emphasis on business development in China [6] - Companies are increasingly inclined to pursue co-development models as clinical data becomes more robust, indicating a trend towards strategic partnerships in the industry [6]

Core Insights - The QDII funds market has shown strong performance in the first ten months of the year, with 95.1% of the 650 comparable funds reporting net value increases, while only 32 funds experienced declines [1] Fund Performance - The top-performing QDII funds include Huatai-PineBridge Hong Kong Advantage Selected Mixed A and C, both achieving returns of 117.54% and 117.53% respectively [1] - A total of 10 QDII funds recorded gains exceeding 78%, with E Fund's Global Growth Selected Mixed A and C (USD and RMB) each surpassing 83% [2][3] - The leading funds in the innovation drug sector have significantly contributed to the overall performance, with notable funds like the GF CSI Hong Kong Innovation Drug ETF and others achieving returns between 78.11% and 88.09% [3] Investment Focus - The investment strategy of the top-performing funds emphasizes sectors such as innovative pharmaceuticals and high-barrier medical equipment, targeting companies with global competitiveness and growth potential [1][3] - The top holdings of the leading funds include major players in the biotech and pharmaceutical industries, such as TSMC, NVIDIA, and Alibaba [2][3] Market Trends - The innovation drug sector has rebounded, leading to a broad increase in related stocks, which has positively impacted the performance of funds heavily invested in this area [1][3] - Conversely, funds focused on oil and gas, as well as real estate, have underperformed, indicating a sector rotation within the QDII market [4]

宁波长阳科技股份有限公司 2025 年第四次临时股东大会会议资料 证券代码：688299 证券简称：长阳科技 宁波长阳科技股份有限公司 2025 年第四次临时股东大会会议资料 2025 年 11 月 宁波长阳科技股份有限公司 2025 年第四次临时股东大会会议资料 宁波长阳科技股份有限公司 2025 年第四次临时股东大会会议资料目录 | 宁波长阳科技股份有限公司 | 2025 年第四次临时股东大会会议须知 | 1 | | --- | --- | --- | | 宁波长阳科技股份有限公司 | 2025 年第四次临时股东大会会议议程 | 3 | | 议案一：关于取消监事会、增加董事会人数并修订〈公司章程〉的议案 | | 5 | | 议案二：关于修订和制定公司部分治理制度的议案 | | 7 | 宁波长阳科技股份有限公司 2025 年第四次临时股东大会会议资料 宁波长阳科技股份有限公司 2025 年第四次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则》以及《宁波长阳科技股份有限公司章 ...

Core Viewpoint - Changyang Technology is a leading global enterprise in optical reflective films, with a strong market share and investment value due to its comprehensive technology in the reflective film industry [1] Group 1: Business Overview - Established on November 16, 2010, and listed on the Shanghai Stock Exchange on November 6, 2019, Changyang Technology is based in Ningbo, Zhejiang Province [1] - The company specializes in the research, production, and sales of reflective films, backplane base films, optical base films, and other special functional films, operating within the electronic-optical optoelectronics-panel sector [1] Group 2: Financial Performance - For Q3 2025, Changyang Technology reported a revenue of 809 million yuan, ranking 28th among 38 companies in the industry, while the top company, BOE Technology Group, achieved 154.55 billion yuan in revenue [2] - The net profit for the same period was -5.34 million yuan, placing the company 26th in the industry, with the leading company, BOE Technology Group, reporting a net profit of 4.40 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 38.15%, lower than the previous year's 39.64% and below the industry average of 45.77%, indicating good solvency [3] - The gross profit margin for Q3 2025 was 30.58%, an increase from 23.92% in the previous year and above the industry average of 14.89%, reflecting strong profitability [3] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 50.56% to 22,600, while the average number of circulating A-shares held per account decreased by 33.58% to 12,700 [5]